Telmisartan
(Redirected from Micardis)
| Drug monograph · NCLEX study reference | |
| Trade names | Micardis |
|---|---|
| Therapeutic class | Antihypertensive |
| Pharmacologic class | ARB |
| Onset / peak / duration | Peak effect about 4 weeks; duration beyond 24 hours. |
| Half-life / level | Half-life about 24 hours; no routine level. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | Yes (see Safety) |
| Antidote / reversal | None specific. |
| Pregnancy / lactation | Contraindicated. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Telmisartan (brand name Micardis) — Antihypertensive; ARB.
Identification
- Therapeutic class: Antihypertensive.
- Pharmacologic class: ARB.
Pharmacology
- Mechanism of action: Same AT1 blockade; longest acting ARB.
- Onset / peak / duration: Peak effect about 4 weeks; duration beyond 24 hours.
- Half-life / therapeutic level: Half-life about 24 hours; no routine level.
Clinical use
- Indications: Hypertension, cardiovascular risk reduction.
- Usual dose, route, frequency: 20 to 80 mg PO once daily.
- Maximum dose / adjustments: Max 80 mg/day; caution in hepatic impairment.
Safety
- Contraindications: Pregnancy, biliary obstruction, aliskiren in diabetes.
- Black box warning: Fetal toxicity.
- Interactions: Digoxin (raises digoxin levels), class ARB interactions.
- Pregnancy / lactation: Contraindicated.
- High-alert: No.
Adverse effects
- Common side effects: Dizziness, back pain, sinus symptoms.
- Serious effects to report: Angioedema, hyperkalemia, renal impairment.
- Antidote / reversal: None specific.
Nursing process
- Assessment before administration: Blood pressure, potassium, renal function, pregnancy status.
- Interventions during therapy: Monitor digoxin if co-administered.
- Monitor: Blood pressure, potassium, renal function.
- Evaluation / expected outcome: Sustained blood pressure control.
Patient teaching
- Patient teaching: Once-daily long-acting agent.
- Notify provider if: Swelling, severe dizziness, pregnancy.
- Administration tips: With or without food.